MeSH D002177 - candidiasis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Voriconazole | Voriconazole | 2012-04-06 | |||
| Glenmark Pharmaceuticals | Voriconazole | Voriconazole | 2015-09-02 | |||
| Mylan | Voriconazole | Voriconazole | 2010-04-22 | |||
| Sandoz | Voriconazole | Voriconazole | 2012-05-30 | |||
| Merck Sharp & Dohme | Caspofungin | Cancidas (previously Caspofungin MSD) | 2001-10-23 | |||
| Posaconazole | Noxafil | 2005-10-25 | $209 M | Q2/23-Q1/24 | ||
| Posaconazole | Posaconazole SP | 2005-10-25 | ||||
| Pfizer | Anidulafungin | Ecalta | 2007-09-20 | |||
| Voriconazole | Vfend | 2002-03-19 | $187 M | Y2023 | ||
| Aurobindo Pharma | Voriconazole | Voriconazole | 2016-01-22 | |||
| Ajanta Pharma | Voriconazole | Voriconazole | 2016-05-24 | |||
| Rising Pharmaceuticals | Voriconazole | Voriconazole | 2013-05-28 |
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
50%2/4
Phase 2
77%10/13
Phase 3
76%19/25
Approved: 8Overall Success rate: 29%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use